|
|
|
Search published articles |
|
|
Showing 2 results for Diabetic Nephropathy
Nasser Aghamohammadzadeh (md), Farzad Najafipour (md), Akbar Aliasgharzadeh (md), Amir Bahrami (md), Mitra Niafar (md), Majid Mobasseri (md), Mehdi Amiri (md), Leila Baghlar (md), Volume 11, Issue 1 (3-2009)
Abstract
Background and Objective: Diabetes mellitus is the most frequent cause of chronic renal failure. Microalbuminuria is the first clinically important sign of renal impairment in diabetes mellitus. The main pathophysiology of diabetic nephropathy is not understood. This study was done on 100 patients with type 2 diabetes for determination of the prevalence of diabetic nephropathy with urine albumin assay in Sina Hospital in Tabriz, North-West of Iran. Materials and Methods: In this discriptive study, 100 patients with type 2 diabetes whome consecutively referred to Endocrine and Diabetes Clinic of Sina Medical Center in Tabriz were enrolled. At the first visit clinical and biochemical parameters such as systolic and diastolic blood pressure, age, sex, body weight, length, body mass index, FBS, HbA1C, plasma creatinine, urine microalbumin and urinary creatinine were measured. FBS, HbA1C, plasma creatinine, urine microalbumin and urinary creatinine measurements repeated every 2 months up to three times during the study. Patients with confounding factors such as uncontrolled hypertension, urinary tract infection, congestive heart failure and hyperlipidemia were excluded. Results: The prevalence of diabetic nephropathy was 36% in our patients. There were not statistically significant differences in age and sex and diastolic – systolic blood pressure and creatinine between nephropathy and, non-nephropathy groups. There was significant differences in body mass index between two sex groups, females were more obese than males. Mean duration of diabetes in diabetic nephropathy group and in diabetic patients without nephropathy were 12.4±8.1 and 9.1±5.5 respectively (P<0.05). Comparison of HbA1c, FBS and drugs used for diabetes treatment were not significant differences between these groups. Conclusion: This study showed that prevalence of diabetic nephropathy was higher than other studies, although there were not significant differences between FBS, HbA1c and hypertension in patients with and without diabetic nephropathy.
Zahra Karampour Gebchag , Reza Heidari , Seyyed Meysam Abtahi-Froushani , Farah Farokhi , Volume 21, Issue 2 (7-2019)
Abstract
Background and Objective: Diabetic mellitus nephropathy is one of the most important implication factors in kidney´s physiological function in diabetes mellitus. Having major role in filtration, in hyperglycemic condition kidney has shown more damages in comparison with other tissues. This study was done to determine the effect of combined Atorvastatin and Zinc oxide on the biochemical and histopathological alterations in kidney of diabetic rats.
Methods: In this experimental study, 40 female Wistar rats were randomly allocated into five groups including normal control (NC), diabetic control (DC), diabetic rats treated with atorvastatin (20mg/kg/bw daily, orally) (D+A), Zinc oxide (30mg/kg/bw daily, orally) (D+Z) and combination of each drug in half dose (daily, orally) (D+A+Z). Diabetes induced in rats by a single intraperitoneal injection of 60mg/kg/bw streptozotocin-diabetic.Animals treated for one month. At the end of the study, kidney weight and body weight and biochemical factors including creatinine and urea were measured to assess renal function. For determing the histopathology of kidney tissue, sections with 4-5 micrometer were stained with hematoxylin and eosin.
Results: The level of serum creatinine and urea was significantly increased in diabetic rats in compare to controls (P<0.05). Treatment of diabetic rats with half doses of combination of atorvastatin and Zinc oxide reduced the level of creatinine, urea and renal tissue damage in comparision with diabetic rats without treatment (P<0.05).
Conclusion: This study showed that the combination of atorvastatin and Zinc oxide has effect on controlling diabetic nephropathy.
|
|